European drug regulators offer wave of positive recommendations following Leqembi reversalnews2024-11-15T17:44:05+00:00November 15th, 2024|Endpoints News|
Adaptimmune to ‘redefine’ itself as a sarcoma biotech, cuts a third of staffersnews2024-11-15T11:56:34+00:00November 15th, 2024|Endpoints News|
Lilly sues US government over proposed 340B rebate modelnews2024-11-15T04:12:18+00:00November 15th, 2024|Endpoints News|
President-elect Trump selects Robert F. Kennedy Jr. to lead HHSnews2024-11-14T21:06:43+00:00November 14th, 2024|Endpoints News|
FDA says Merz’s social media promotion with Nate Berkus is ‘misleading’news2024-11-14T20:44:46+00:00November 14th, 2024|Endpoints News|
Gilead to close Philadelphia and Seattle offices, make job cutsnews2024-11-14T20:30:36+00:00November 14th, 2024|Endpoints News|
European drug regulator reverses opinion on Eisai and Biogen’s Alzheimer’s drugnews2024-11-14T20:11:55+00:00November 14th, 2024|Endpoints News|
Louisiana’s Bill Cassidy named next chair of Senate health committeenews2024-11-14T18:05:52+00:00November 14th, 2024|Endpoints News|
As bluebird projects more commercial demand, the biotech continues to seek cashnews2024-11-14T15:11:21+00:00November 14th, 2024|Endpoints News|
BeiGene rebrands as BeOne Medicines, dropping name’s link to Chinanews2024-11-14T15:05:14+00:00November 14th, 2024|Endpoints News|
